Archived explainer. For the current picture see today's SLS page.
Why Is SELLAS LIFE SCIENCES (SLS) Stock Up Today?
By the Top Tier Newswire AI Desk · August 27, 2026 at 10:13 AM ET · reviewed against 2 wire stories
SELLAS LIFE SCIENCES (SLS) is up +9.98% in the latest session. Our newswire has captured 2 stories on SLS across 1 source in the last 36 hours, with AI sentiment reading bullish (avg 60/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
SLS stock is up 9.98% to $15.10 as of the latest trade, driven by a combination of regulatory developments in the biotech sector and new institutional investment. The stock opened with a 1.9% gap up and has continued to climb throughout the session, reaching a high of $15.13. The move follows recent news of a pancreatic cancer drug approval and a disclosed stake from a major U.S. pension fund.
What Happened
The U.S. Food and Drug Administration approved RASONQUE, a once-daily pill for adults with metastatic pancreatic cancer who have already tried chemotherapy or cannot take multi-drug regimens. This development has drawn attention to SLS’s own leukemia pipeline, as traders speculate on the broader implications for biotech innovation. Separately, Virginia Retirement System disclosed stakes in SLS and IBRX with a combined value of nearly $909,000, signaling institutional interest. These two developments have contributed to the sharp rise in SLS stock. Additionally, recent arbitration rulings against SELLAS Life Sciences, including an order to pay approximately $1M in legal fees, appear to have been overshadowed by the positive news flow.
What The Data Shows
The stock opened at $13.99 and has traded as high as $15.13, with volume reaching 2.0 million shares, or 0.2x the 3-month daily average. Over the past 8 sessions, the stock has moved up 3.8% from $13.00 to $13.50. The 52-week range is $1.39 to $15.88, and the stock has printed 15 fresh 52-week highs and 7 fresh 52-week lows on August 27, 2026. The market cap is $2.8 billion, and the company remains unprofitable with an EPS TTM of -0.21.
What To Watch
SLS has no upcoming earnings date scheduled. Traders will likely monitor the breadth of coverage and any further developments in its leukemia pipeline or regulatory landscape.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
SLS · Aug 27 session (5-min) · +10.85% vs prior close · updated 8:49 PM ETAI sentiment, last 36h · averaged over 2 stories · 60/100 bullish
The headlines behind the move
Story flow · 2 stories on the wire, last 36h · hover or tap a dot for the headline
17d agoStocktwits NewsBULLISH 63Product/PR
Sellas Traders See Pancreatic Cancer Race After RVMD’s Drug Approval — But Near-Term Focus Remains On SLS’s Leukemia Pipeline
On Wednesday, the U.S. Food and Drug Administration approved RASONQUE, a once-daily pill for adults with metastatic pancreatic cancer who have already tried chemotherapy or cannot take multi-drug regimens.
18d agoStocktwits NewsBULLISH 56General
SLS, IBRX Catch The Eye Of A Major US Pension Fund — And Big Clinical Catalysts Are On The Horizon
Virginia Retirement System disclosed SLS and IBRX stakes worth nearly $909,000 combined.
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →